

Substitute for form 1449A/PTO

PTO/SB08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT.

(use as many sheets as necessary)

Complete if Known

Application Number	10/541,526
Filing Date	July 7, 2005
First Named Inventor	Stephen Robert Bloom
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	AI 9250US

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
ADK			0 619 332		Kuraray Co., Ltd.	10-12-1994		
↓			0 795 562		Kyowa Hakko Kogyo Co., Ltd.	09-17-1997		
			WO 93/19175		Thorens Bernard	09-30-1993		
			WO 99/43707		Novo Nordisk A/S	09-02-1999		
			WO 00/42026		Novonordisk AS and Agouron Pharma	07-20-2000		
	ADK			WO 00/59887		Neurogen Corporation	10-12-2000	


**Examiner's
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Please type a page number (+) inside this box -->



PTO/SB08A (10-88)
Approved for use through 10/31/99. OMB 0631-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	10/541,626
Filing Date	July 7, 2005
First Named Inventor	Stephen Robert Bloom
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	AI 9250US

Sheet 3 of 3

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
ADK		ADRIAN, et al., "Effect of peptide YY on gastric, pancreatic, and biliary function in humans," <i>Gastroenterology</i> , 89:494-499 (1985).	
		CUMMINGS, et al., "A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans," <i>Diabetes</i> , 50:1714-1719 (2001).	
		DAKIN, et al., "Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats," <i>Am J Physiol Endocrinol Metab.</i> , 283(6):E1173-7 (2002).	
		DAKIN, et al., "Oxyntomodulin inhibits food intake in the rat," <i>Endocrinology</i> , 142:4244-4250 (2001).	
		ENG, et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from <i>Heloderma suspectum</i> venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas," <i>J Biol Chem</i> , 267:7402-7405 (1992).	
		ENGLISH, "Food fails to suppress ghrelin levels in obese humans," <i>J Clin Endocrinol Metab</i> , 87:2984-87 (2002).	
		GHATEI, et al., "Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract," <i>J Clin Endocrinol Metab</i> , 57:488-495 (1983).	
		KREYMANN, "Glucagon-like peptide-1 7-36: a physiological incretin in man," <i>Lancet</i> , 2:1300-1304 (1987).	
		TATEMOTO, "Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion," <i>Proc. Natl. Acad. Sci.</i> , 79:2514-8 (1982).	
		UESAKA, et al., "Glucagon-like peptide isolated from the eel intestine: effects on atrial beating," <i>J Exp Biol.</i> , 204(Pt 17):3019-26 (2001).	
		WREN, et al., "Ghrelin enhances appetite and increases food intake in humans," <i>J Clin Endocrinol Metab</i> , 86:5992-5 (2001).	
ADK		WYNNE, et al., "Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial," <i>Diabetes</i> , 54(8):2390-5 (2005).	

Examiner's Signature	/Andrew D. Kosar/	Date Considered	02/07/2007
----------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

